The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 293, Issue 3, 2007, Pages

  Demyanets, Svitlana ^a   Kaun, Christoph ^a   Rychli, Kathrin ^a   Rega, Gersina ^a   Pfaffenberger, Stefan ^a   Afonyushkin, Taras ^a   Bochkov, Valery N ^a   Maurer, Gerald ^a   Huber, Kurt ^b   Wojta, Johann ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Cardiology and Emergency Medicine   (Austria)

^c Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

Author keywords

Glycoprotein 130; Oncostatin M; Plasminogen; Plasminogen activator inhibitor; Smooth muscle cells

Indexed keywords

JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ONCOSTATIN M; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE B; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE INHIBITOR;

AORTA; APOPTOSIS; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RESTENOSIS; SMOOTH MUSCLE FIBER; THROMBOGENESIS; VASCULAR SMOOTH MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AORTA; CELL PROLIFERATION; CELLS, CULTURED; CHROMONES; CORONARY VESSELS; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 3; MORPHOLINES; MUSCLE, SMOOTH, VASCULAR; ONCOSTATIN M; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 34548427894     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01366.2006     Document Type: Article

References (47)

1. Banfi C, Eriksson P, Giandomenico G, Mussoni L, Sironi L, Hamsten A, Tremoli E. Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: insights into the signaling pathway. Diabetes 50: 1522-1530, 2001.
2. Bernard C, Merval R, Lebret M, Delerive P, Dusanter-Fourt I, Lehoux S, Creminon C, Staels B, Maclouf J, Tedgui A. Oncostatin M induces interleukin-6 and cyclooxygenase-2 expression in human vascular smooth muscle cells: synergy with interleukin-1beta. Circ Res 85: 1124-1131, 1999.
3. Bochkov VN, Mechtcheriakova D, Lucerna M, Huber J, Malli R, Graier WF, Hofer E, Binder BR, Leitinger N. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. Blood 99: 199-206, 2002.
4. Cao Z, Liu L, Van Winkle DM. Met5-enkephalin-induced cardioprotection occurs via transactivation of EGFR and activation of PI3K. Am J Physiol Heart Circ Physiol 288: H1955-H1964, 2005.
5. Chen SH, Benveniste EN. Oncostatin M: a pleiotropic cytokine in the central nervous system. Cytokine Growth Factor Rev 15: 379-391, 2004.
6. Chen Y, Budd RC, Kelm RJ Jr, Sobel BE, Schneider DJ. Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1. Arterioscler Thromb Vasc Biol 26: 1777-1783, 2006.
7. de Waard V, Arkenbout EK, Carmeliet P, Lindner V, Pannekoek H. Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model. Arterioscler Thromb Vasc Biol 22: 1978-1983, 2002.
8. Grove RI, Eberhardt C, Abid S, Mazzucco C, Liu J, Kiener P, Todaro G, Shoyab M. Oncostatin M is a mitogen for rabbit vascular smooth muscle cells. Proc Natl Acad Sci USA 90: 823-827, 1993.
9. Hamilton JA, Leizer T, Piccoli DS, Royston KM, Butler DM, Croatto M. Oncostatin M stimulates urokinase-type plasminogen activator activity in human synovial fibroblasts. Biochem Biophys Res Commun 180: 652-659, 1991.
10. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2: 3-9, 1987.
11. Hansson GK, Jonasson L, Lojsthed B, Stemme S, Kocher O, Gabbiani G. Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Atherosclerosis 72: 135-141, 1988.
12. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20, 2003.
13. Kasza A, Kiss DL, Gopalan S, Xu W, Rydel RE, Koj A, Kordula T. Mechanism of plasminogen activator inhibitor-1 regulation by oncostatin M and interleukin-1 in human astrocytes. J Neurochem 83: 696-703, 2002.
14. Keeton MR, Curriden SA, van Zonneveld AJ, Loskutoff DJ. Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem 266: 23048-23052, 1991.
15. Klouche M, Rose-John S, Schmiedt W, Bhakdi S. Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation 101: 1799-1805, 2000.
16. Kodama H, Fukuda K, Pan J, Sano M, Takahashi T, Kato T, Makino S, Manabe T, Murata M, Ogawa S. Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy. Am J Physiol Heart Circ Physiol 279: H1635-H1644, 2000.
17. Lahiri T, Laporte JD, Moore PE, Panettieri RA Jr, Shore SA. Interleukin-6 family cytokines: signaling and effects in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 280: L1225-L1232, 2001.
18. Lee E, Vaughan DE, Parikh SH, Grodzinsky AJ, Libby P, Lark MW, Lee RT. Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. Circ Res 78: 44-49, 1996.
19. Libby P. Inflammation in atherosclerosis. Nature 420: 868-874, 2002.
20. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 3: 35-45, 2005.
21. Loy JK, Davidson TJ, Berry KK, Macmaster JF, Danle B, Durham SK. Oncostatin M: development of a pleiotropic cytokine. Toxicol Pathol 27: 151-155, 1999.
22. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EK. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 13: 1090-1100, 1993.
23. Luttun A, Lupu F, Storkebaum E, Hoylaerts MF, Moons L, Crawley J, Bono F, Poole AR, Tipping P, Herbert JM, Collen D, Carmeliet P. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 22: 499-505, 2002.
24. Macfelda K, Weiss TW, Kaun C, Breuss JM, Zorn G, Oberndorfer U, Voegele-Kadletz M, Huber-Beckmann R, Ullrich R, Binder BR, Losert UM, Maurer G, Pacher R, Huber K, Wojta J. Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes. J Mol Cell Cardiol 34: 1681-1691, 2002.
25. Modur V, Feldhaus MJ, Weyrich AS, Jicha DL, Prescott SM, Zimmerman GA, McIntyre TM. Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest 100: 158-168, 1997.
26. Nagata T, Kai H, Shibata R, Koga M, Yoshimura A, Imaizumi T. Oncostatin M, an interleukin-6 family cytokine, upregulates matrix metalloproteinase-9 through the mitogen-activated protein kinase kinaseextracellular signal-regulated kinase pathway in cultured smooth muscle cells. Arterioscler Thromb Vasc Biol 23: 588-593, 2003.
27. Nicholl SM, Roztocil E, Davies MG. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol 4: 101-116, 2006.
28. Nishibe T, Parry G, Ishida A, Aziz S, Murray J, Patel Y, Rahman S, Strand K, Saito K, Saito Y, Hammond WP, Savidge GF, Mackman N, Wijelath ES. Oncostatin M promotes biphasic tissue factor expression in smooth muscle cells: evidence for Erk-1/2 activation. Blood 97: 692-699, 2001.
29. Oh H, Fujio Y, Kunisada K, Hirota H, Matsui H, Kishimoto T, Yamauchi-Takihara K. Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes. J Biol Chem 273: 9703-9710, 1998.
30. Okada H, Woodcock-Mitchell J, Fujii S. Leukaemia inhibitory factor and oncostatin M modulate expression of urokinase plasminogen activator and fibrinogen. Coron Artery Dis 7: 561-567, 1996.
31. Padro T, Emeis JJ, Steins M, Schmid KW, Kienast J. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 15: 893-902, 1995.
32. Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15: 237-254, 2004.
33. Rega G, Kaun C, Weiss TW, Demyanets S, Zorn G, Kastl SP, Steiner S, Seidinger D, Kopp CW, Frey M, Roehle R, Maurer G, Huber K, Wojta J. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue. Circulation 111: 1938-1945, 2005.
34. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340: 115-126, 1999.
35. Rossignol P, Luttun A, Martin-Ventura JL, Lupu F, Carmeliet P, Collen D, Angles-Cano E, Lijnen HR. Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques. J Thromb Haemost 4: 664-670, 2006.
36. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study Atherosclerosis Risk in Communities Study. Circulation 91: 284-290, 1995.
37. Samarakoon R, Higgins CE, Higgins SP, Kutz SM, Higgins PJ. Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-beta1-stimulated smooth muscle cells is pp60(c-src)/ MEK-dependent. J Cell Physiol 204: 236-246, 2005.
38. Schneider DJ, Hayes M, Wadsworth M, Taatjes H, Rincon M, Taatjes DJ, Sobel BE. Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type 1 (PAI-1). J Histochem Cytochem 52: 1091-1099, 2004.
39. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 89: 6998-7002, 1992.
40. Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox. Circulation 99: 2496-2498, 1999.
41. Sobel BE, Taatjes DJ, Schneider DJ. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 23: 1979-1989, 2003.
42. Spence MJ, Streiff R, Day D, Ma Y. Oncostatin M induces tissue-type plasminogen activator and plasminogen activator inhibitor-1 in Calu-1 lung carcinoma cells. Cytokine 18: 26-34, 2002.
43. Staiger H, Staiger K, Stefan N, Wahl HG, Machicao F, Kellerer M, Haring HU. Palmitate-induced interleukin-6 expression in human coronary artery endothelial cells. Diabetes 53: 3209-3216, 2004.
44. Strand K, Murray J, Aziz S, Ishida A, Rahman S, Patel Y, Cardona C, Hammond WP, Savidge G, Wijelath ES. Induction of the urokinase plasminogen activator system by oncostatin M promotes endothelial migration. J Cell Biochem 79: 239-248, 2000.
45. Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 149: 39-52, 2003.
46. Wiesbauer F, Kaun C, Zorn G, Maurer G, Huber K, Wojta J. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol 135: 284-292, 2002.
47. Wojta J, Gallicchio M, Zoellner H, Hufnagl P, Last K, Filonzi EL, Binder BR, Hamilton JA, McGrath K. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells. Thromb Haemost 70: 469-474, 1993.